Rapamycin attenuates the development of chronic hypoxia-induced pulmonary hypertension in mice

来源 :2011中华医学会呼吸病学年会暨第十二次全国呼吸病学学术会议 | 被引量 : 0次 | 上传用户:coolyangbo
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Background:Pulmonary hypertension (PH) is characterized by a progressive increase in pulmonary vascular resistance, structural remodeling of the pulmonary vasculature, finally, right ventricular failure and death. One trigger of PH is hypoxia which chronically leads to vascular proliferation and remodeling. The proliferation of smooth muscle cells is now recognized to play a significant role in the remodelling of small pulmonary arteries. The mammalian target of rapamycin (mTOR) also known as mechanistic target of rapamycin has been reported to be an important signal pathway which involevd in cell proliferation. However, whether rapamycin could attenuate hypoxia-induced pulmonary hypertension by inhibiting cell proliferation and the possible signal pathways are still unknown.Objective:To investigate the effect of rapamycin on hypoxia-induced pulmonary hypertension andits possible mechanism.Methods:8-week male C57BL/6 mice were exposed to either normobaric hypoxia(10% oxygen) ornormoxic condition (21% oxygen), with or without rapamycin (3mglkg*d, i.p.) orcarboxymethylcellulose as vehicle from the first day. At 0, 1,2, 3 and 4 weeks(6 mice in eachgroup for each time point), The right ventricular pressure(RVSP) of mice was measured by usingclosed-chest cardiac puncture technique, and then, the mice were sacrificed, heart and lung werecollected. The index of right ventricular hypertrophy(RVHI), that is the ratio of the right ventricularweight to left ventricular weight plus the interventricular septum was calculated. Histological andimmunohistochemical measurement were used to assess the distal vascular remodeling.Results:The RVSP and RVHI of control mice were 16.94 1 0.30 mmHg and 0.21810.0047respectively. After 1, 2, 3 and 4 weeks housed in hypoxia, the RVSP gradually increased to19.03士0.69 mmHg (12.64%±5%, p<0.01), 21.22±0.71 mmHg (25.71%±6%, p<0.01), 21.64±0.49 mmHg (28.04%t4%, p<0.01) and 22.27士0.19 mmHg (31.69%±3%, p<0.01) compared with 0 week. TheRVHI gradually raised to 0.2324±0.0034 (6.8%±2.5%, p>0.05), 0.2527±0.0081 (16.49%士6%,p
其他文献
慢性阻塞性肺疾病(COPD)是一种以气流受限不完全可逆为特征的慢性呼吸系统疾病。COPD急性加重期(AECOPD)是指在疾病过程中短期内患者咳嗽、咳痰、气短或喘息加重,痰量增多、呈脓性或粘液脓性,可伴有发热等炎症明显加重的表现。在急性发作期,由于冷空气、细菌、病毒感染等因素刺激,气道梗阻加重,更进一步加重气流受限,导致低氧血症及肺功能下降。近年我科采用布地奈德混悬液联合沙丁胺醇溶液雾化吸入治疗AE
目的:分析未接受治疗的OSAHS患者7年随访前后睡眠监测及临床特点的变化。方法:研究对象为2002年承德市区流调及应用便携式睡眠监测仪确诊的99例OSAHS患者,包括中年组63例(男45例,女18例),老年组36例(男22例,女14例),均未接受治疗,7年后再次随访,行睡眠呼吸监测并分析其临床特点变化。结果:中年组OSAHS患者白天嗜睡发生率与老年组比较,差异无统计学意义(P>0.05);老年组O
目的:我们研究旨在探讨在中老年肥胖男性阻塞性睡眠呼吸暂停低通气综合征(OSAHS)是否为代谢综合征(MS)及其成分的独立危险因素。方法:选择性收集了因打鼾并怀疑有睡眠呼吸暂停至我科行睡眠呼吸监测(PSG)的40岁肥胖以上男性即体质量指数(Body massindex, BMI>=25kg/m2,的男性病人,并予匹配各组BMI,入选者予行整夜PSG监测,于次日晨起予抽空腹血行血糖、血脂等相关代谢指标
目的:本研究通过检测支气管哮喘大鼠模型中Radical Fringe的表达以及一些Tregs的相关指标,探究Notch的胞外调节分子Fringe是否与Tregs有一定关系,旨在阐明哮喘的发病机理。方法:1.哮喘大鼠模型建立及验证:采用随机对照原则将40只大鼠分成哮喘组和对照组,其中哮喘组20只,对照组20只。哮喘组于第0天和第7天皮下和腹腔注射0.02%OVA混悬液lml和百日咳菌苗0. 6ml(
变应性鼻炎(AR)是以鼻粘膜接触变应原后出现的IgE诱导的炎症反应,AR和哮喘同属呼吸道变应性疾病,AR是成年哮喘发病的明确的风险因素。值得重视的是,部分变应性鼻炎患者虽然没有临床哮喘,但却存在气道高反应性(AHR)和嗜酸粒细胞炎症,这部分病例发展成临床哮喘的危险性明显升高;早期发现早期治疗,有可能预防哮喘的发生发展;对其发生机制、气道炎症特征的研究,可有助于进一步阐明鼻炎与哮喘的内在联系。
目的:鉴定重组葎草花粉主要变应原pTSX2的免疫特性,并初步评价其安全性。方法:应用western Blotting鉴定重组葎草花粉主要变应原pTSX2的免疫特性:用葎草花粉变应性哮喘患者的血清作为一抗行Western blotting试验;重组葎草花粉主要变应原pTSX2免疫正常小鼠鉴定其免疫原性。结果:Western Blotting结果表明重组蓬草花粉主要变应原pTSX2可与多数(约70%)
目的:本研究应用GAP-43作为神经再生及重塑标志物,对其进行深入研究有利于对哮喘气道重构深入认识,为气道重构的治疗提供新靶点。方法:(1)动物分组和哮喘动物模型的制备:健康雌性清洁级BALB/c小鼠30只,4-6周龄,按随机数字表法分为三组:A组:正常对照组;B组:经典模型组:C组:慢性延长组,每组10只。试验开始0, 7, 14天B组C组分别给予致敏液200u1(0. 04%OVA50u1+1
Background:Current researches have shown that pulmonary vascular remodeling is one of the most important mechanisms for CTEPH, which share the homoioplastic pathological characteristics with IPAH. It
Objective:Find out polymorphisms associated with CTEPH and/or PTE.Ascertain whether fibrin resistance to lysis occurs in CTEPH and/or PTE.Find out the influence of fibrinogen Aa Thr312Ala polymorphism
肺泡蛋白沉积症(Pulmonary Alveolar Proteinosis,PAP)是一种肺泡和细支气管腔内充满不可溶性富磷脂蛋白质物质沉积为特征的少见浸润性肺弥漫性疾病。是一种发病率低、发病机制不明、临床表现不典型、极易误诊、难确诊的疾病。本科于2010年5月收治首例肺泡蛋白沉积症病人,行大容量全肺灌洗术,术后患者胸闷、气促明显减轻,复查肺功能、胸部CT明显好转,疗效确切。本文对这些临床资料进